Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Renal Denervation with a catheter-based procedure · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Renal Denervation with a catheter-based procedure | DEVICE | Disruption of the renal nerves with a catheter-based procedure |
Inclusion Criteria: * Systolic blood pressure of 160 mmHg or greater * On 3 or more antihypertensive medications * On dialysis for more than 6 months Exclusion Criteria: * Renal artery abnormalities * Known secondary hypertension attributable to a cause other than sleep apnea * MI, angina, CVA wi...
Renal Denervation with a catheter-based procedure is used for chronic kidney failure, specifically in patients with end stage renal disease who also have refractory hypertension. The procedure is being studied as a potential treatment for this patient population.
Renal Denervation with a catheter-based procedure is being developed by Medtronic plc, a medical technology company traded on the New York Stock Exchange under the ticker symbol MDT.
Renal Denervation with a catheter-based procedure is in Phase 1 clinical development. It is an investigational procedure and has not been approved by the FDA. One Phase 1 trial has been completed.
Renal Denervation with a catheter-based procedure has one completed clinical trial, identified as NCT00753116. This trial was titled 'Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension' and enrolled 20 participants in the United States.
Renal Denervation with a catheter-based procedure is a specific form of renal denervation, a technique that uses a catheter to disrupt renal nerves. The trial NCT00753116 studied this procedure in patients with chronic kidney failure and refractory hypertension.